医学
比索洛尔
心绞痛
β受体阻滞剂
心力衰竭
心脏病学
心肌梗塞
血压
重症监护医学
疾病
内科学
原发性高血压
作者
Giuseppe Mancia,Sverre E. Kjeldsen,Reinhold Kreutz,Atul Pathak,Guıdo Grassı,Murray Esler
出处
期刊:Hypertension
[Ovid Technologies (Wolters Kluwer)]
日期:2022-05-11
卷期号:79 (6): 1153-1166
被引量:49
标识
DOI:10.1161/hypertensionaha.122.19020
摘要
Several hypertension guidelines have removed beta-blockers from their previous position as first-choice drugs for the treatment of hypertension. However, this downgrading may not be justified by available evidence because beta-blockers lower blood pressure as effectively as other major antihypertensive drugs and have solid documentation in preventing cardiovascular complications. Suspected inconveniences of beta-blockers such as increased risk of depression or erectile dysfunction may have been overemphasized, while patients with chronic obstructive pulmonary disease or peripheral artery disease, that is, conditions in which their use was previously restricted, will benefit from beta-blocker therapy. Besides, evidence that from early to late phases, hypertension is accompanied by activation of the sympathetic nervous system makes beta-blockers pathophysiologically an appropriate treatment in hypertension. Beta-blockers have favorable effects on a variety of clinical conditions that may coexist with hypertension, making their use either as specific treatment or as co-treatment potentially common in clinical practice. Guidelines typically limit recommendations on specific beta-blocker use to cardiac conditions including angina pectoris, postmyocardial infarction, or heart failure, with little or no mention of the additional cardiovascular or noncardiovascular conditions in which these drugs may be needed or preferred. In the present narrative review, we focus on multiple additional diseases and conditions that may occur and affect patients with hypertension, often more frequently than people without hypertension, and that may favor the choice of beta-blocker. Notwithstanding, beta-blockers represent an in-homogenous group of drugs and choosing beta-blockers with documented effect in prevention and treatment of disease is important for first choice in guidelines.
科研通智能强力驱动
Strongly Powered by AbleSci AI